Topic: Prostate cancer active surveillance
Document Owner: Head of Evidence and Quality Hub, National Cancer Control Programme (NCCP)
National Group: National Cancer Control Programme
Effective From: 15 May 2025
Unfortunately, you are using an outdated browser. Please, upgrade your browser to improve your experience with HSE. The list of supported browsers:
The purpose of this National Clinical Guideline is to provide evidence-based recommendations on the active surveillance of patients with prostate cancer through the integration of the best research evidence with clinical expertise, patient values and experiences.